Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of “Hold” from Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has been given a consensus rating of “Hold” by the fourteen analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $41.3333.

Several analysts recently weighed in on CNTA shares. Lifesci Capital cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. B. Riley Financial cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a report on Monday, April 13th. Finally, Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA opened at $39.69 on Friday. The company has a market cap of $5.92 billion, a P/E ratio of -22.17 and a beta of 1.11. The firm’s fifty day moving average price is $39.65 and its two-hundred day moving average price is $30.73. Centessa Pharmaceuticals has a one year low of $11.77 and a one year high of $40.26. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities analysts expect that Centessa Pharmaceuticals will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider owned 62,085 shares in the company, valued at $1,629,731.25. This trade represents a 65.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 309,112 shares of company stock worth $8,424,535. Corporate insiders own 4.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. acquired a new position in Centessa Pharmaceuticals during the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at $36,000. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares in the last quarter. Finally, Knott David M Jr acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at $100,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.